Security National Bank of SO Dak Boosts Stock Position in AbbVie Inc. (NYSE:ABBV)

Security National Bank of SO Dak increased its holdings in AbbVie Inc. (NYSE:ABBV) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,012 shares of the company’s stock after purchasing an additional 795 shares during the quarter. AbbVie makes up approximately 1.7% of Security National Bank of SO Dak’s holdings, making the stock its 14th largest holding. Security National Bank of SO Dak’s holdings in AbbVie were worth $3,023,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Fiduciary Advisors Inc. purchased a new stake in shares of AbbVie in the 4th quarter worth about $29,000. EnRich Financial Partners LLC lifted its holdings in AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after buying an additional 110 shares during the period. Promus Capital LLC bought a new stake in AbbVie during the 4th quarter valued at approximately $30,000. Bradley & Co. Private Wealth Management LLC purchased a new position in shares of AbbVie during the 4th quarter worth approximately $31,000. Finally, Prudent Man Investment Management Inc. bought a new position in shares of AbbVie in the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 2.3%

AbbVie stock opened at $181.52 on Friday. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $218.66. The stock has a fifty day simple moving average of $191.89 and a two-hundred day simple moving average of $187.11. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The firm has a market cap of $321.10 billion, a price-to-earnings ratio of 75.63, a PEG ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The company had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same period last year, the company earned $2.31 EPS. AbbVie’s revenue for the quarter was up 8.4% on a year-over-year basis. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Insider Activity

In related news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the transaction, the executive vice president now owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the sale, the executive vice president now owns 44,284 shares in the company, valued at $8,985,223.60. This represents a 40.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 113,471 shares of company stock valued at $23,426,451 in the last 90 days. 0.25% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of several research reports. UBS Group lifted their price target on AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley boosted their target price on shares of AbbVie from $241.00 to $250.00 and gave the company an “overweight” rating in a report on Monday, April 28th. Erste Group Bank upgraded shares of AbbVie to a “strong-buy” rating in a research note on Monday, March 17th. Wells Fargo & Company boosted their price objective on shares of AbbVie from $210.00 to $240.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, BMO Capital Markets raised their target price on shares of AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, seventeen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $210.95.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.